These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 31195050)

  • 1. Gene editing based hearing impairment research and therapeutics.
    Kang W; Sun Z; Zhao X; Wang X; Tao Y; Wu H
    Neurosci Lett; 2019 Sep; 709():134326. PubMed ID: 31195050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
    Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
    J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in genome editing for genetic hearing loss.
    Ding N; Lee S; Lieber-Kotz M; Yang J; Gao X
    Adv Drug Deliv Rev; 2021 Jan; 168():118-133. PubMed ID: 32387678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genetics and hearing loss－from gene function to gene therapy].
    Wang QJ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Dec; 58(Z1):41-51. PubMed ID: 38726521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation.
    Zhu W; Du W; Rameshbabu AP; Armstrong AM; Silver S; Kim Y; Wei W; Shu Y; Liu X; Lewis MA; Steel KP; Chen ZY
    Sci Transl Med; 2024 Jul; 16(755):eadn0689. PubMed ID: 38985856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in gene therapy hold promise for treating hereditary hearing loss.
    Jiang L; Wang D; He Y; Shu Y
    Mol Ther; 2023 Apr; 31(4):934-950. PubMed ID: 36755494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
    Gao X; Tao Y; Lamas V; Huang M; Yeh WH; Pan B; Hu YJ; Hu JH; Thompson DB; Shu Y; Li Y; Wang H; Yang S; Xu Q; Polley DB; Liberman MC; Kong WJ; Holt JR; Chen ZY; Liu DR
    Nature; 2018 Jan; 553(7687):217-221. PubMed ID: 29258297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
    Mills EM; Barlow VL; Luk LYP; Tsai YH
    Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-mediated genome editing: From basic research to translational medicine.
    Jacinto FV; Link W; Ferreira BI
    J Cell Mol Med; 2020 Apr; 24(7):3766-3778. PubMed ID: 32096600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous zygotic inactivation of multiple genes in mouse through CRISPR/Cas9-mediated base editing.
    Zhang H; Pan H; Zhou C; Wei Y; Ying W; Li S; Wang G; Li C; Ren Y; Li G; Ding X; Sun Y; Li GL; Song L; Li Y; Yang H; Liu Z
    Development; 2018 Oct; 145(20):. PubMed ID: 30275281
    [No Abstract]   [Full Text] [Related]  

  • 16. How CRISPR gene editing could help treat Alzheimer's.
    Thompson T
    Nature; 2024 Jan; 625(7993):13-14. PubMed ID: 38082131
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in genome editing of stem cells for drug discovery and therapeutic application.
    Lee J; Bayarsaikhan D; Bayarsaikhan G; Kim JS; Schwarzbach E; Lee B
    Pharmacol Ther; 2020 May; 209():107501. PubMed ID: 32061705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications.
    Molla KA; Yang Y
    Trends Biotechnol; 2019 Oct; 37(10):1121-1142. PubMed ID: 30995964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene editing using CRISPR-Cas9 for the treatment of lung cancer.
    Castillo A
    Colomb Med (Cali); 2016 Dec; 47(4):178-180. PubMed ID: 28293040
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo.
    Tao Y; Lamas V; Du W; Zhu W; Li Y; Whittaker MN; Zuris JA; Thompson DB; Rameshbabu AP; Shu Y; Gao X; Hu JH; Pei C; Kong WJ; Liu X; Wu H; Kleinstiver BP; Liu DR; Chen ZY
    Nat Commun; 2023 Aug; 14(1):4928. PubMed ID: 37582836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.